ENROLLMENT
45%
156 / 350 patients
BUDGET
50%
$3.5M /$ $7.0M
SCREEN FAILURES
30.4%
vs 25.0% benchmark
ACTIVE SITES
3
7.0 total FTE
MILESTONES
2/6
33% complete
ENROLLMENT TRENDS
No projection data available
BUDGET BREAKDOWN
TOTAL BUDGET
$7.00M
CONSUMED
$3.50M
50%
REMAINING
$3.50M
+3% INF$3.60M
Passthrough
$2.80M (40%)
40%
Investigator Fees
$1.75M (25%)
25%
Consumed
$3.50M (50%)
50%
Remaining
$3.50M (50%)
50%
AVG COST PER PATIENT
$20,000
CURRENT BURN RATE
$22,435.897/pt
SITE PERFORMANCE
| SITE | STATUS | ENROLLMENT | TARGET | PROGRESS | SCREEN FAIL | FTE |
|---|---|---|---|---|---|---|
Nashville | 68 | 150 | 45% | 32.0% | 3 | |
Knoxville | 58 | 120 | 48% | 29.3% | 2.5 | |
Memphis | 30 | 80 | 38% | 28.6% | 1.5 |
RISK REGISTER
HIGH PRIORITY (2)
20
Screen failure rate significantly above benchmark
P:5 × I:4 • ENROLLMENT
Mitigation: Revise inclusion criteria with sponsor; add cognitive screening pre-consent
16
Budget overrun due to extended enrollment period
P:4 × I:4 • BUDGET
Mitigation: Negotiate budget amendment with sponsor
MEDIUM PRIORITY (1)
9
Staff turnover at Memphis site impacting enrollment
P:3 × I:3 • OPERATIONAL
MILESTONES
First Patient Enrolled
Target: 1/20/2024 • Completed: 1/18/2024
25% Enrollment
Target: 9/1/2024 • Completed: 10/15/2024
50% Enrollment
Target: 5/1/2025
75% Enrollment
Target: 1/1/2026
Last Patient Enrolled
Target: 6/30/2026
Database Lock
Target: 12/31/2026
TRIAL INFORMATION
Protocol Version:1.2
Sponsor:NeuroScience Corp
CRO:ICON plc
Therapeutic Area:Neurology
Start Date:1/10/2024
Est. Completion:12/31/2026
Passthrough:$2.80M
Per Patient:$8,000
Investigator Fees:$5,000/pt